|
1
|
Galaal K, Al Moundhri M, Bryant A, Lopes
AD and Lawrie TA: Adjuvant chemotherapy for advanced endometrial
cancer. Cochrane Database Syst Rev. 5:CD0106812014.PubMed/NCBI
|
|
2
|
Emily K, Clark L, Franasiak J, Bae-Jump V
and Gehrig P: Obesity portends a significantly higher risk of
recurrence in women with grade 3 endometrial carcinoma: A call to
action. Gynecolo Oncol. 125(Supp 1): S1582012. View Article : Google Scholar
|
|
3
|
Sorosky JI: Endometrial cancer. Obstetr
Gynecol. 120:383–397. 2012. View Article : Google Scholar
|
|
4
|
Tangjitgamol S1, Anderson BO, See HT,
Lertbutsayanukul C, Sirisabya N, Manchana T, Ilancheran A, Lee KM,
Lim SE, Chia YN, et al: Asian Oncology Summit: Management of
endometrial cancer in Asia: consensus statement from the Asian
Oncology Summit 2009. Lancet Oncol. 10:1119–1127. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Felix AS, Stone RA, Bowser R, Chivukula M,
Edwards RP, Weissfeld JL and Linkov F: Comparison of survival
outcomes between patients with malignant mixed mullerian tumors and
high-grade endometrioid, clear cell, and papillary serous
endometrial cancers. Int J Gynecol Cancer. 21:877–884. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Del Carmen MG, Boruta DM II and Schorge
JO: Recurrent endometrial cancer. Clin Obstet Gynecol. 54:266–277.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Morrow CP, Bundy BN, Kurman RJ, Creasman
WT, Heller P, Homesley HD and Graham JE: Relationship between
surgical-pathological risk factors and outcome in clinical stage I
and II carcinoma of the endometrium: A gynecologic oncology group
study. Gynecol Oncol. 40:55–65. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Keys HM, Roberts JA, Brunetto VL, Zaino
RJ, Spirtos NM, Bloss JD, Pearlman A, Maiman MA and Bell JG:
Gynecologic Oncology Group: A phase III trial of surgery with or
without adjunctive external pelvic radiation therapy in
intermediate risk endometrial adenocarcinoma: A gynecologic
oncology group study. Gynecol Oncol. 92:744–751. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ioffe Y, Delic L, Amneus M, Leuchter R,
Karlan B, Li A, Walsh C, Lentz S, Farias-Eisner R and Cass I:
Before and after GOG 99: Did our practice patterns for treatment of
intermediate risk endometrial adenocarcinoma change? Gynecol Oncol.
116:5952010. View Article : Google Scholar
|
|
10
|
Rankins NC, Secord AA, Jewell E,
Havrilesky LJ, Soper JT and Myers E: Cost-effectiveness of adjuvant
radiotherapy in intermediate risk endometrial cancer. Gynecol
Oncol. 106:388–393. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Edge S, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: Gynecologic Sites - Corpus Uteri. AJCC
Cancer Staging Manual (7th). Springer. (New York). 4032010.
|
|
12
|
Kim HJ, Kim TJ, Lee YY, Choi CH, Lee JW,
Bae DS and Kim BG: A comparison of uterine papillary serous, clear
cell carcinomas, and grade 3 endometrioid corpus cancers using 2009
FIGO staging system. J Gynecol Oncol. 24:120–127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gayar OH, Patel S, Schultz D, Mahan M,
Rasool N and Elshaikh MA: The impact of tumor grade on survival end
points and patterns of recurrence of 949 patients with early-stage
endometrioid carcinoma: A single institution study. Int J Gynecol
Cancer. 24:97–101. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tejerizo-García A, Jiménez-López JS,
Muñoz-González JL, Bartolomé-Sotillos S, Marqueta-Marqués L,
López-González G and Gómez JF: Overall survival and disease-free
survival in endometrial cancer: Prognostic factors in 276 patients.
Onco Targets Ther. 9:1305–1313. 2013.PubMed/NCBI
|
|
15
|
Creutzberg CL, van Putten WL, Koper PC,
Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KA, Lutgens
LC, van den Bergh AC, van de Steen-Banasik E, et al: Surgery and
postoperative radiotherapy versus surgery alone for patients with
stage-1 endometrial carcinoma: Multicentre randomised trial. PORTEC
study group. Post operative radiation therapy in endometrial
carcinoma. Lancet. 355:1404–1411. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rasool N, Fader AN, Seamon L, Neubauer NL,
Shahin FA, Alexander HA, Moore K, Moxley K, Secord AA, Kunos C, et
al: Stage I, grade 3 endometrioid adenocarcinoma of the
endometrium: An analysis of clinical outcomes and patterns of
recurrence. Gynecol Oncol. 116:10–14. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Long KC, Zhou Q, Hensley ML, Alektiar KM,
Gomez J, Gardner GJ, Chi DS, Barakat RR and Abu-Rustum NR: Patterns
of recurrence in 1988 FIGO stage IC endometrioid endometrial
cancer. Gynecol Oncol. 125:99–102. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mariani A, Webb MJ, Keeney GL, Lesnick TG
and Podratz KC: Surgical stage I endometrial cancer: Predictors of
distant failure and death. Gynecol Oncol. 87:274–280. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lindauer J, Fowler JM, Manolitsas TP,
Copeland LJ, Eaton LA, Ramirez NC and Cohn DE: Is there a
prognostic difference between depth of myometrial invasion and the
tumor-free distance from the uterine serosa in endometrial cancer?
Gynecol Oncol. 91:547–551. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chattopadhyay S, Cross P, Nayar A, Galaal
K and Naik R: Tumor size: A better independent predictor of distant
failure and death than depth of myometrial invasion in
international federation of gynecology and obstetrics stage I
endometrioid endometrial cancer. Int J Gynecol Cancer. 23:690–697.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zaino RJ, Kurman RJ, Diana KL and Morrow
CP: Pathologic models to predict outcome for women with endometrial
adenocarcinoma: The importance of the distinction between surgical
stage and clinical stage-a gynecologic oncology group study.
Cancer. 77:1115–1121. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Larson DM, Connor GP, Broste SK, Krawisz
BR and Johnson KK: Prognostic significance of gross myometrial
invasion with endometrial cancer. Obstet Gynecol. 88:394–398. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Patel S, Portelance L, Gilbert L, Tan L,
Stanimir G, Duclos M and Souhami L: Analysis of prognostic factors
and patterns of recurrence in patients with pathologic stage III
endometrial cancer. Int J Radiat Oncol Biol Phys. 68:1438–1445.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mariani A, Webb MJ, Keeney GL, Calori G
and Podratz KC: Hematogenous dissemination in corpus cancer.
Gynecol Oncol. 80:233–238. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gemer O, Uriev L, Harkovsky T, Peled R,
Ben-Dor D, Barak F and Seqal S: The significance of the degree of
myometrial invasion in patients with stage IB endometrial cancer.
Eur J Gynaecol Oncol. 25:336–338. 2004.PubMed/NCBI
|
|
26
|
Alektiar KM, McKee A, Lin O, Venkatraman
E, Zelefsky MJ, Mychalczak BR, Mckee B, Hoskins WJ and Barakat RR:
The significance of the amount of myometrial invasion in patients
with Stage IB endometrial carcinoma. Cancer. 95:316–321. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Baloglu A, Bezircioglu I, Cetinkaya B and
Hicyilmaz L: Prospective clinical study of the association between
plasma level of free IGF-1 and myometrial invasion min patients
with endometrial adenocarcinoma. Ginekol Pol. 81:501–505.
2010.PubMed/NCBI
|
|
28
|
Schneider J, Martinez-Arribas F and
Torrejón R: Nup88 expression is associated with myometrial invasion
in endometrial carcinoma. Int J Gynecol Cancer. 20:804–808. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Takama F, Kanuma T, Wang D, Kagami I and
Mizunuma H: Oestrogen receptor beta expression and depth of
myometrial invasion in human endometrial cancer. Br J Cancer.
84:545–549. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Soeda S, Nakamura N, Ozeki T, Nishiyama H,
Hojo H, Yamada H, Abe M and Sato A: Tumor-associated macrophages
correlate with vascular space invasion and myometrial invasion in
endometrial carcinoma. Gynecol Oncol. 109:122–128. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sakai K, Yamagami W, Susumu N, Nomura H,
Kataoka F, Banno K, Tsuda H and Aoki D: Pathological factors
associated with omental metastases in endometrial cancer. Eur J
Gynaecol Oncol. 36:397–401. 2015.PubMed/NCBI
|
|
32
|
Turan T, Hizli D, Sarici S, Boran N,
Gundogdu B, Karadag B, Tulunay G and Kose MF: Is it possible to
predict para-aortic lymph node metastasis in endometrial cancer?
Eur J Obstet Gynecol Reprod Biol. 158:274–279. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hétu V, Petignat P, Wu Y, Drouin P,
Sauthier P, Provencher D and Gauthier P: Positive adnexal or
uterine serosal involvement in stage IIIC endometrial cancer is an
adverse factor for recurrence. Gynecol Obstet Invest. 67:173–177.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jobsen JJ, Ten Cate L Naudin, Lybeert ML,
Scholten A, van der Steen-Banasik EM, van der Palen J, Kroese MC
Stenfert, Slot A, Schutter EM and Siesling S: Outcome of
Endometrial Cancer Stage IIIA with Adnexa or Serosal Involvement
Only. Obstet Gynecol Int. 2011:9625182011.PubMed/NCBI
|
|
35
|
Guntupalli SR, Zighelboim I, Kizer NT,
Zhang Q, Powell MA, Thaker PH, Goodfellow PJ and Mutch DG:
Lymphovascular space invasion is an independent risk factor for
nodal disease and poor outcomes in endometrioid endometrial cancer.
Gynecol Oncol. 124:31–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Maggi R, Lissoni A, Spina F, et al:
Adjuvant chemotherapy vs radiotherapy in high-risk endometrial
carcinoma: results of a randomised trial. British journal of
cancer. 95:266–271. 2006. View Article : Google Scholar : PubMed/NCBI
|
